Dianon charged $4.8 million for mischarging Medicare:
This article was originally published in Clinica
Dianon Systems of Stratford, Connecticut, is to pay $4.8m under a settlement agreement with the US Department of Justice. The fine follows a DoJ investigation of the cancer testing laboratory firm's billing of Medicare and other federal healthcare programmes for medically unnecessary tests. The company had set aside $5.5m in the third quarter to cover the payment and associated legal costs. Dianon is being acquired by Laboratory Corporation of America for $600m.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.